Success Metrics

Completion Rate

0%(0/5)

Active Trials

0(0%)

Terminated

5(71%)

Phase Distribution

Ph phase_1

43%

Ph phase_2

29%

Ph phase_3

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 3Large-scale testing

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 6 finished

Non-Completion Rate

100.0%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(6)

Other(1)

Detailed Status

Terminated5

unknown1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (50.0%)

Phase 22 (33.3%)

Phase 31 (16.7%)

Trials by Status

unknown114%

terminated571%

withdrawn114%

Recent Activity

0 active trials

Showing 5 of 7

terminatedphase_2

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

NCT02147990

terminatedphase_1

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01526928

terminatedphase_3

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

NCT02322281

terminatedphase_1

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

NCT02630186

terminatedphase_1

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT02580708

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT02147990Phase 2

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

Terminated

NCT01526928Phase 1

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Terminated

NCT02322281Phase 3

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Terminated

NCT02630186Phase 1

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Terminated

NCT02580708Phase 1

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Terminated

NCT02547675

Rociletinib (CO-1686) USA Expanded Access Program

Unknown

NCT02705339Phase 2

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7